FDA approves omalizumab (Xolair) label expansion: now indicated for reducing allergic reactions to multiple foods in adults and children aged 1 year and older
FDA has approved a supplemental BLA expanding the indication for omalizumab (Xolair; Genentech/Novartis) to reduce the risk of allergic reactions — including anaphylaxis — caused by accidental exposure to one or more foods in patients aged 1 year and older with IgE-mediated food allergy. The approval is based on the OUTMATCH phase 3 trial, which enrolled patients with allergy to peanut and at least two other foods. Omalizumab is not a cure for food allergy and does not eliminate the need for epinephrine; patients must continue to avoid allergen foods and carry epinephrine auto-injectors.
On 16 October 2026, FDA approved a supplemental BLA expanding the indication of omalizumab (Xolair; Genentech/Novartis) ↗ to reduce the risk of allergic reactions, including anaphylaxis, caused by accidental exposure to one or more foods in patients aged 1 year and older with IgE-mediated food allergy. This is the first FDA-approved drug treatment for food allergy across multiple allergens simultaneously. Omalizumab is not curative — it does not desensitise the immune system to individual foods. Patients must continue strict allergen avoidance and carry epinephrine auto-injectors (e.g. EpiPen) at all times. Updated prescribing information on DailyMed ↗.
OUTMATCH trial: evidence basis
The approval was based on the OUTMATCH phase 3 randomised controlled trial (NCT04045301; ClinicalTrials.gov ↗). Enrolled patients were aged 1–55 years with confirmed IgE-mediated allergy to peanut and at least 2 of 6 other foods (tree nuts, milk, egg, wheat, shellfish, finfish). Omalizumab 75–600 mg SC every 2–4 weeks (weight/IgE-dosed) versus placebo for 16 weeks. The primary endpoint — tolerating a single dose of ≥600 mg peanut protein without dose-limiting symptoms at week 16 — was met by 67% of the omalizumab group vs 7% placebo (p<0.001). Across the 6 foods, 47–66% of omalizumab patients achieved the tolerance threshold vs 0–11% placebo. Published in NEJM 2024 (PubMed) ↗.
Mechanism and IgE pharmacology
Omalizumab is a humanised anti-IgE monoclonal antibody. It binds to the Cε3 domain of free IgE, preventing IgE from attaching to the high-affinity IgE receptor (FcεRI) on mast cells and basophils. This reduces FcεRI expression on effector cells and raises the threshold of allergen needed to trigger degranulation. For food allergy, this means a higher dose of accidental exposure is required to produce anaphylaxis — providing a safety buffer but not complete protection. Background on IgE biology: NCBI StatPearls: Allergy and IgE ↗. For context on drug allergy and hypersensitivity mechanisms, see our drug allergy guide.
Practical prescribing: dosing, REMS, and patient counselling
Xolair dosing for food allergy is weight- and total-IgE-based (same dosing table as for chronic urticaria and allergic asthma). Administration is subcutaneous injection in a healthcare setting, with 30-minute observation post-dose due to anaphylaxis risk from the injection itself. Key counselling points: (1) carry epinephrine at all times — omalizumab reduces but does not eliminate anaphylaxis risk; (2) continue strict food avoidance; (3) benefit may diminish after treatment discontinuation; (4) full effect typically requires 16–24 weeks. Xolair remains on the FDA REMS programme. The Asthma and Allergy Foundation of America ↗ provides patient education. Report adverse events to FDA MedWatch ↗.
FAQ
What does FDA approval mean?
FDA approval means the agency has determined, based on scientific evidence submitted by the manufacturer, that a drug's benefits outweigh its known risks for a specific indication and patient population. The review process includes evaluation of clinical trial data, manufacturing quality, and proposed labelling. See the FDA drug approval process overview ↗.
Does approval mean the drug is available immediately?
Not always. Commercial launch timelines depend on manufacturing scale-up, pricing, and distribution. REMS-restricted drugs ↗ require prescriber or pharmacy enrolment before the product can be dispensed. Rare disease drugs may also have limited initial supply. Check the manufacturer's website or RxNav ↗ for availability status.